

Clinical trials of direct oral anticoagulant (DAO) for DVT prophylaxis in medical patients

TrialResults-center www.trialresultscenter.org

1 Extended-duration prophylaxis

Trial	Treatments	Patients	Trials design and methods
rivaroxaban vs placebo			
MARINER <i>ongoing</i> [NCT02111564] n=NA follow-up:	rivaroxaban thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, versus placebo	high-risk medical patients	

References

MARINER, :

Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. *Thromb Haemost* 2016;115:1240-8 [[26842902](#)]

2 NOAC

Trial	Treatments	Patients	Trials design and methods
apixaban vs enoxaparin			
ADOPT , 2011 [NCT00457002] n=3255/3273 follow-up: 30 days	apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days versus enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days	acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days	double-blind
betrixaban vs enoxaparin			
APEX , 2016 [NCT01583218] n=3759/3754 follow-up:	betrixaban (at a dose of 80 mg once daily) for 35 to 42 days versus subcutaneous enoxaparin (at a dose of 40 mg once daily) for 104 days	-	double-blind
rivaroxaban vs enoxaparin			

continued...

Trial	Treatments	Patients	Trials design and methods
MAGELLAN , 2011 <i>unpublished</i> [NCT00571649] n=4050/4051 follow-up: 35 days	rivaroxaban 10 mg once daily for 35 days versus subcutaneous enoxaparin 40 mg once daily for 10 days	patients hospitalized for acute medical illness	Parallel groups double-blind

References

ADOPT, 2011:

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77 [22077144]

APEX, 2016:

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016;: [27232649]

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016 May 27;: [27232649]

MAGELLAN, 2011:

Cohen AT, Spiro TE, Bller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013 Feb 7;368:513-23 [23388003] [10.1056/NEJMoa1111096](#)

2

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.